Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of “Moderate Buy” by Brokerages

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) has been given an average rating of “Moderate Buy” by the eight ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $66.6667.

A number of equities research analysts have recently issued reports on RVPH shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Reviva Pharmaceuticals in a report on Tuesday, April 21st. Wall Street Zen raised shares of Reviva Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, April 11th. Maxim Group cut shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, April 8th. Finally, D. Boral Capital cut shares of Reviva Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, March 5th.

Reviva Pharmaceuticals Stock Performance

Shares of RVPH stock opened at $0.41 on Tuesday. The firm’s 50-day moving average is $0.71 and its 200-day moving average is $5.06. The stock has a market cap of $5.36 million, a price-to-earnings ratio of -0.10 and a beta of 0.75. Reviva Pharmaceuticals has a 52-week low of $0.26 and a 52-week high of $23.00.

Reviva Pharmaceuticals (NASDAQ:RVPH) last issued its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.10). Sell-side analysts predict that Reviva Pharmaceuticals will post -2.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of RVPH. Armistice Capital LLC bought a new position in Reviva Pharmaceuticals in the 2nd quarter valued at about $1,026,000. Geode Capital Management LLC raised its holdings in Reviva Pharmaceuticals by 87.6% in the 4th quarter. Geode Capital Management LLC now owns 1,048,954 shares of the company’s stock valued at $293,000 after acquiring an additional 489,711 shares during the period. State Street Corp raised its holdings in Reviva Pharmaceuticals by 202.4% in the 4th quarter. State Street Corp now owns 383,200 shares of the company’s stock valued at $107,000 after acquiring an additional 256,500 shares during the period. Millennium Management LLC raised its holdings in Reviva Pharmaceuticals by 15.0% in the 3rd quarter. Millennium Management LLC now owns 1,711,221 shares of the company’s stock valued at $631,000 after acquiring an additional 223,178 shares during the period. Finally, Lido Advisors LLC bought a new position in Reviva Pharmaceuticals in the 3rd quarter valued at about $37,000. 63.18% of the stock is owned by institutional investors.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals, Inc (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings.